{"meshTags":["Antineoplastic Agents, Hormonal","Aromatase Inhibitors","Breast Neoplasms","Chemotherapy, Adjuvant","Female","Humans","Tamoxifen"],"meshMinor":["Antineoplastic Agents, Hormonal","Aromatase Inhibitors","Breast Neoplasms","Chemotherapy, Adjuvant","Female","Humans","Tamoxifen"],"genes":["aromatase"],"organisms":["9606"],"publicationTypes":["English Abstract","Journal Article","Review"],"abstract":"Hormonal therapy has been the first systemic treatment against breast cancer. Up to now Tamoxifen and ovarian supression/ablation were the best optionts we had to treat early breast cancer as advancer disease. The advent of aromatase inhibitors, new SERMS and antistrogen Fulvestrant have supoused a great advance in the treatment of this disease and at the same time have complicated the election of the optimal drug for each patient. This article tries to review the aviable treatment options insiting on its indications.","title":"[Hormonal therapy in breast cancer].","pubmedId":"18578196"}